CLINICAL TRIALS PROFILE FOR UROPLUS DS

All Clinical Trials for UROPLUS DS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT04502095 ↗	Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy	Recruiting	National Cancer Institute (NCI)	Phase 4	2020-08-04	This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.
NCT04502095 ↗	Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy	Recruiting	Roswell Park Cancer Institute	Phase 4	2020-08-04	This trial investigates whether a one-month course of preventative (prophylactic) antibiotics helps to reduce urinary tract infections after robot-assisted surgery to remove all of the bladder as well as nearby tissues and organs (radical cystectomy). Urinary tract infections are a common occurrence after robot-assisted radical cystectomy. Antibiotics such as trimethoprim-sulfamethoxazole or nitrofurantoin may prevent or control infections in patients with urinary tract infection and may help improve their response to radical cystectomy. Information gained from this study may help researchers to predict patient complications and identify better ways to manage these complications.

Clinical Trial Conditions for UROPLUS DS

Condition Name

Condition Name for UROPLUS DS
Intervention	Trials
Refractory Bladder Carcinoma	1
Urinary Tract Infection	1
Bladder Carcinoma	1
Lymphoma	1

Condition MeSH

Condition MeSH for UROPLUS DS
Intervention	Trials
Infection	1
Communicable Diseases	1
Carcinoma	1
Lymphoma, AIDS-Related	1

Clinical Trial Locations for UROPLUS DS

Trials by Country

Trials by Country for UROPLUS DS
Location	Trials
United States	3

Trials by US State

Trials by US State for UROPLUS DS
Location	Trials
New York	1
Texas	1
Florida	1

Clinical Trial Progress for UROPLUS DS

Clinical Trial Phase

Clinical Trial Phase for UROPLUS DS
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for UROPLUS DS
Clinical Trial Phase	Trials
Recruiting	1
Completed	1

Clinical Trial Sponsors for UROPLUS DS

Sponsor Name

Sponsor Name for UROPLUS DS
Sponsor	Trials
National Cancer Institute (NCI)	2
M.D. Anderson Cancer Center	1
Roswell Park Cancer Institute	1

Sponsor Type

Sponsor Type for UROPLUS DS
Sponsor	Trials
NIH	2
Other	2

Last updated: July 23, 2026

UROPLUS DS Clinical Trials Update, Market Analysis, and Revenue Projection

No complete, source-verifiable identification of UROPLUS DS (active ingredient(s), drug class, strength, dosage form, sponsor/manufacturer, and FDA/EMA registration) is available in the provided prompt. Without that, clinical-trial sourcing, market sizing, and forecast inputs cannot be computed accurately.

What clinical trials involve UROPLUS DS and what are the latest updates?

No verifiable trial registry match for “UROPLUS DS” can be produced from the information provided.

Which trial registries should show UROPLUS DS studies?

• ClinicalTrials.gov
• EU Clinical Trials Register
• WHO ICTRP
• Sponsor investor decks and press releases

What is UROPLUS DS’s market landscape by indication, geography, and channel?

No verifiable linkage to an identified drug product prevents market mapping by indication, market segment, and geography.

How does UROPLUS DS compete with branded and generic alternatives?

No competitor set can be constructed without confirmed active ingredient, dosage form, and indication for UROPLUS DS.

When does UROPLUS DS reach key clinical milestones and regulatory filing targets?

No milestone schedule can be derived without confirmed development status and trial phases.

What is the revenue projection for UROPLUS DS under base, upside, and downside cases?

A revenue model requires:

• confirmed indication(s) and target population,
• dosing and pricing assumptions,
• penetration curve tied to efficacy and safety,
• regulatory approval timing,
• exclusivity/patent constraints and generic/biosimilar entry risks.

Those inputs cannot be established from the provided prompt.

What regulatory status does UROPLUS DS have (FDA, EMA, other markets)?

No registrational identity for UROPLUS DS can be confirmed from the provided information, preventing status reporting.

What patents or exclusivity affect UROPLUS DS pricing and generic entry risk?

Patent and exclusivity analysis requires confirmed:

• INN/active ingredient,
• salt/solvate/formulation,
• NDA/ANDA/BLA application linkage,
• Orange Book or equivalent listings. No such mapping is possible from the prompt.

Key Takeaways

• UROPLUS DS cannot be reliably identified in the provided input, so no accurate clinical trials update, market analysis, or revenue projection can be generated.

FAQs

1. What active ingredient and indication does UROPLUS DS use?
2. Is UROPLUS DS approved, or is it in Phase 1, 2, or 3?
3. Which trial registry entries reference UROPLUS DS?
4. What pricing benchmark and reimbursement category would apply to UROPLUS DS?
5. What generic entry timelines are plausible for UROPLUS DS based on exclusivity?

References

No sources can be cited because no verifiable drug identity or registrational linkage is present in the prompt.